Host: Matt Birnholz, MD

Guest: Ajai Chari, MD

Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Birnholz is joined by Dr. Ajai Chari.

USA-OCF-80679